Interleukin 15 - Admune Therapeutics
Alternative Names: Heterodimeric IL-15; Heterodimeric Interleukin 15; hetIL-15; IL 15; NIZ985; sIL 15RaLatest Information Update: 25 Jan 2024
At a glance
- Originator Admune Therapeutics
- Developer Admune Therapeutics; National Cancer Institute (USA); Novartis
- Class Adjuvants; Immunotherapies; Interleukins
- Mechanism of Action Immunomodulators; Interleukin stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 27 Dec 2023 Novartis Pharmaceuticals terminates the phase I trial in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Belgium, Germany, Italy, Japan, Spain, Taiwan and USA due to business decision (NCT04261439)
- 03 Nov 2023 Interleukin 15 is still in phase I trials for Solid tumours in Japan and USA
- 20 Oct 2023 Updated adverse events and pharmacokinetics data from a phase I/Ib trial in Solid tumours presented at the 48th European Society for Medical Oncology Congress (ESMO-2023)